Haemonetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. 

CEO
Christopher A. Simon
CEOChristopher A. Simon
Employees
3,009
Employees3,009
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1971
Founded1971
Employees
3,009
Employees3,009

HAE Key Statistics

Market cap
3.55B
Market cap3.55B
Price-Earnings ratio
38.20
Price-Earnings ratio38.20
Dividend yield
Dividend yield
Average volume
588.62K
Average volume588.62K
High today
$79.57
High today$79.57
Low today
$77.59
Low today$77.59
Open price
$78.50
Open price$78.50
Volume
563.14K
Volume563.14K
52 Week high
$87.32
52 Week high$87.32
52 Week low
$47.32
52 Week low$47.32

Stock Snapshot

As of today, Haemonetics(HAE) shares are valued at $78.17. The company's market cap stands at 3.55B, with a P/E ratio of 38.20.

As of 2026-07-20, Haemonetics(HAE) stock has fluctuated between $77.59 and $79.57. The current price stands at $78.17, placing the stock +0.7% above today's low and -1.8% off the high.

The Haemonetics(HAE)'s current trading volume is 563.14K, compared to an average daily volume of 588.62K.

In the last year, Haemonetics(HAE) shares hit a 52-week high of $87.32 and a 52-week low of $47.32.

In the last year, Haemonetics(HAE) shares hit a 52-week high of $87.32 and a 52-week low of $47.32.

HAE News

Simply Wall St 3d
Haemonetics Could Be 10% Undervalued On Its Margin Expansion Story

Haemonetics (HAE) has drawn attention after recent share price moves, including a gain of about 7% over the past month and roughly 26% over the past 3 months. T...

Haemonetics Could Be 10% Undervalued On Its Margin Expansion Story
TipRanks 5d
Haemonetics price target raised to $90 from $85 at Mizuho

Mizuho analyst Anthony Petrone raised the firm’s price target on Haemonetics (HAE) to $90 from $85 and keeps an Outperform rating on the shares. The firm adjust...

Analyst ratings

67%

of 12 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own HAE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.